{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"49.0","upperLimit":"79.7","value":"66.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"description":"The Kaplan-Meier estimate of EFS is calculated from enrollment date to first occurrence of disease progression, disease recurrence, second malignant neoplasm, or death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with classic histology (WHO Grade II) supratentorial ependymoma who have undergone microscopic gross total resection (GTR1) or achieved CR either after first or second resection or after post-operative induction chemotherapy are assigned to observation. For patients without GTR1, induction chemotherapy is comprised of vincristine intravenously (IV) over 1 minute on days 1 and 8 of cycles 1 and 2, carboplatin IV over 15-60 minutes on day 1 of cycles 1 and 2, and cyclophosphamide IV over 30-60 minutes on days 1-2 of cycle 1 only. Patients also receive etoposide IV over 60-120 minutes on days 1-3 of cycle 2 only. Cycle 1 continues for 3 weeks and cycle 2 continues for 4 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm I: Observation"}],"paramType":"NUMBER","populationDescription":"Eligible participants in Arm I","reportingStatus":"POSTED","timeFrame":"Up to 10 years after enrollment. 5-year estimates of EFS are presented.","title":"EFS of Children With Supratentorial Classic Ependymoma Who Achieve Complete Resection at First or Second Surgery or Children Who Achieve Complete Response (CR) After Induction Chemo and Who Are Non-randomly Assigned to Observation","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"percentage of participants"}